Latest Safety News

KGL Resources updates on its Jervois Copper Project optimisations and financing progress, welcoming Resource Capital Fund as a new significant shareholder. The company is capitalising on higher metal prices and exploring critical mineral opportunities.

Race Oncology has secured Investigational New Drug approval from South Korea’s regulatory authority, enabling Phase 1 clinical trials of RC220 in combination with doxorubicin for solid tumour patients across four Korean sites.

QPM Energy has reported its first-ever profit alongside a 12.6% revenue increase and significant growth in gas reserves and electricity generation capacity.

Bio-Gene Technology’s novel acaricide Flavocide demonstrated over 90% mortality against Lyme disease-carrying ticks in lab tests presented by Purdue University, highlighting its potential in public health applications.

Myer Holdings reported a 13.8% revenue increase in FY25, boosted by its acquisition of Apparel Brands, yet faced a statutory net loss of $211.2 million due to goodwill impairment. The integration of Apparel Brands is underway, with strategic growth initiatives in motion.

The European Medicines Agency has approved continuous bi-monthly dosing of CLINUVEL’s SCENESSE® for adult erythropoietic protoporphyria patients, removing previous annual dose limits and aligning Europe with US treatment standards.

INOVIQ Limited has demonstrated that its CAR-NK-exosome therapy kills over 90% of triple-negative breast cancer cells within 10 hours in laboratory tests, validating its potential as a next-generation cancer treatment.

Emyria secures a multi-year funding agreement with Medibank to support its Treatment-Resistant Depression program, marking a first for insurer-backed psychotherapy in Australia.

Lakes Blue Energy reports strong gas shows at its Wombat-5 well in Victoria’s Gippsland Basin, reinforcing hopes for a commercially viable gas development.

X2M Connect has secured a significant contract to digitise water meters for 6,750 Seoul households, marking a key step in the city's ambitious A$240 million smart metering initiative.

CLINUVEL Pharmaceuticals has presented compelling new case studies demonstrating the efficacy of SCENESSE® in treating vitiligo, showing significant and stable repigmentation in patients. These findings, shared at the EADV conference, hint at a potential breakthrough for a condition with limited treatment options.

PARKD Limited has clinched exclusive national rights to prefabricate key modular building components from Fielders, positioning itself to capitalize on booming construction sectors like data centres and self-storage across Australia.